Research ExplorerPublicationsA real-world comparison of docetaxel versus abiraterone acet...

A real-world comparison of docetaxel versus abiraterone acetate for metastatic hormone-sensitive prostate cancer

Standard

A real-world comparison of docetaxel versus abiraterone acetate for metastatic hormone-sensitive prostate cancer. / Tsaur, Igor; Heidegger, Isabel; Bektic, Jasmin; Kafka, Mona; van den Bergh, Roderick C N; Hunting, Jarmo C B; Thomas, Anita; Brandt, Maximilian P; Höfner, Thomas; Debedde, Eliott; Thibault, Constance; Ermacora, Paola; Zattoni, Fabio; Foti, Silvia; Kretschmer, Alexander; Ploussard, Guillaume; Rodler, Severin; von Amsberg, Gunhild; Tilki, Derya; Surcel, Christian; Rosenzweig, Barak; Gadot, Moran; Gandaglia, Giorgio; Dotzauer, Robert; EAU-YAU Prostate Cancer Working Group.

In: CANCER MED-US, Vol. 10, No. 18, 09.2021, p. 6354-6364.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Tsaur, I, Heidegger, I, Bektic, J, Kafka, M, van den Bergh, RCN, Hunting, JCB, Thomas, A, Brandt, MP, Höfner, T, Debedde, E, Thibault, C, Ermacora, P, Zattoni, F, Foti, S, Kretschmer, A, Ploussard, G, Rodler, S, von Amsberg, G, Tilki, D, Surcel, C, Rosenzweig, B, Gadot, M, Gandaglia, G, Dotzauer, R & EAU-YAU Prostate Cancer Working Group 2021, 'A real-world comparison of docetaxel versus abiraterone acetate for metastatic hormone-sensitive prostate cancer', CANCER MED-US, vol. 10, no. 18, pp. 6354-6364. https://doi.org/10.1002/cam4.4184

APA

Tsaur, I., Heidegger, I., Bektic, J., Kafka, M., van den Bergh, R. C. N., Hunting, J. C. B., Thomas, A., Brandt, M. P., Höfner, T., Debedde, E., Thibault, C., Ermacora, P., Zattoni, F., Foti, S., Kretschmer, A., Ploussard, G., Rodler, S., von Amsberg, G., Tilki, D., ... EAU-YAU Prostate Cancer Working Group (2021). A real-world comparison of docetaxel versus abiraterone acetate for metastatic hormone-sensitive prostate cancer. CANCER MED-US, 10(18), 6354-6364. https://doi.org/10.1002/cam4.4184

Vancouver

Tsaur I, Heidegger I, Bektic J, Kafka M, van den Bergh RCN, Hunting JCB et al. A real-world comparison of docetaxel versus abiraterone acetate for metastatic hormone-sensitive prostate cancer. CANCER MED-US. 2021 Sep;10(18):6354-6364. https://doi.org/10.1002/cam4.4184

Bibtex

@article{a04935268b3b437fb6fafc678e107aa9,
title = "A real-world comparison of docetaxel versus abiraterone acetate for metastatic hormone-sensitive prostate cancer",
abstract = "BACKGROUND: Docetaxel (D) or secondary hormonal therapy (SHT) each combined with androgen deprivation therapy (ADT) represent possible treatment options in males with metastasized hormone-sensitive prostate cancer (mHSPC). Real-world data comparing different protocols are lacking yet. Thus, our objective was to compare the efficacy and safety of abiraterone acetate (AA)+ADT versus D+ADT in mHSPC.METHODS: In a retrospective multicenter analysis including males with mHSPC treated with either of the aforementioned protocols, overall survival (OS), progression-free survival 1 (PFS1), and progression-free survival 2 (PFS2) were assessed for both cohorts. Median time to event was tested by Kaplan-Meier method and log-rank test. The Cox-proportional hazards model was used for univariate and multivariate regression analyses.RESULTS: Overall, 196 patients were included. The AA+ADT cohort had a longer PFS1 in the log-rank testing (23 vs. 13 mos., p < 0.001), a longer PFS2 (48 vs. 33 mos., p = 0.006), and longer OS (80 vs. 61 mos., p = 0.040). In the multivariate analyses AA+ADT outperformed D+ADT in terms of PFS1 (HR = 0.34, 95% CI = 0.183-0.623; p = 0.001) and PFS2 (HR = 0.33 95% CI = 0.128-0.827; p = 0.018), respectively, while OS and toxicity rate were similar between both groups.CONCLUSIONS: AA+ADT is mainly associated with a similar efficacy and overall toxicity rate as D+ADT. Further prospective research is required for validation of the clinical value of the observed benefit of AA+ADT for progression-free end-points.",
author = "Igor Tsaur and Isabel Heidegger and Jasmin Bektic and Mona Kafka and {van den Bergh}, {Roderick C N} and Hunting, {Jarmo C B} and Anita Thomas and Brandt, {Maximilian P} and Thomas H{\"o}fner and Eliott Debedde and Constance Thibault and Paola Ermacora and Fabio Zattoni and Silvia Foti and Alexander Kretschmer and Guillaume Ploussard and Severin Rodler and {von Amsberg}, Gunhild and Derya Tilki and Christian Surcel and Barak Rosenzweig and Moran Gadot and Giorgio Gandaglia and Robert Dotzauer and {EAU-YAU Prostate Cancer Working Group}",
note = "{\textcopyright} 2021 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.",
year = "2021",
month = sep,
doi = "10.1002/cam4.4184",
language = "English",
volume = "10",
pages = "6354--6364",
journal = "CANCER MED-US",
issn = "2045-7634",
publisher = "John Wiley and Sons Ltd",
number = "18",

}

RIS

TY - JOUR

T1 - A real-world comparison of docetaxel versus abiraterone acetate for metastatic hormone-sensitive prostate cancer

AU - Tsaur, Igor

AU - Heidegger, Isabel

AU - Bektic, Jasmin

AU - Kafka, Mona

AU - van den Bergh, Roderick C N

AU - Hunting, Jarmo C B

AU - Thomas, Anita

AU - Brandt, Maximilian P

AU - Höfner, Thomas

AU - Debedde, Eliott

AU - Thibault, Constance

AU - Ermacora, Paola

AU - Zattoni, Fabio

AU - Foti, Silvia

AU - Kretschmer, Alexander

AU - Ploussard, Guillaume

AU - Rodler, Severin

AU - von Amsberg, Gunhild

AU - Tilki, Derya

AU - Surcel, Christian

AU - Rosenzweig, Barak

AU - Gadot, Moran

AU - Gandaglia, Giorgio

AU - Dotzauer, Robert

AU - EAU-YAU Prostate Cancer Working Group

N1 - © 2021 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.

PY - 2021/9

Y1 - 2021/9

N2 - BACKGROUND: Docetaxel (D) or secondary hormonal therapy (SHT) each combined with androgen deprivation therapy (ADT) represent possible treatment options in males with metastasized hormone-sensitive prostate cancer (mHSPC). Real-world data comparing different protocols are lacking yet. Thus, our objective was to compare the efficacy and safety of abiraterone acetate (AA)+ADT versus D+ADT in mHSPC.METHODS: In a retrospective multicenter analysis including males with mHSPC treated with either of the aforementioned protocols, overall survival (OS), progression-free survival 1 (PFS1), and progression-free survival 2 (PFS2) were assessed for both cohorts. Median time to event was tested by Kaplan-Meier method and log-rank test. The Cox-proportional hazards model was used for univariate and multivariate regression analyses.RESULTS: Overall, 196 patients were included. The AA+ADT cohort had a longer PFS1 in the log-rank testing (23 vs. 13 mos., p < 0.001), a longer PFS2 (48 vs. 33 mos., p = 0.006), and longer OS (80 vs. 61 mos., p = 0.040). In the multivariate analyses AA+ADT outperformed D+ADT in terms of PFS1 (HR = 0.34, 95% CI = 0.183-0.623; p = 0.001) and PFS2 (HR = 0.33 95% CI = 0.128-0.827; p = 0.018), respectively, while OS and toxicity rate were similar between both groups.CONCLUSIONS: AA+ADT is mainly associated with a similar efficacy and overall toxicity rate as D+ADT. Further prospective research is required for validation of the clinical value of the observed benefit of AA+ADT for progression-free end-points.

AB - BACKGROUND: Docetaxel (D) or secondary hormonal therapy (SHT) each combined with androgen deprivation therapy (ADT) represent possible treatment options in males with metastasized hormone-sensitive prostate cancer (mHSPC). Real-world data comparing different protocols are lacking yet. Thus, our objective was to compare the efficacy and safety of abiraterone acetate (AA)+ADT versus D+ADT in mHSPC.METHODS: In a retrospective multicenter analysis including males with mHSPC treated with either of the aforementioned protocols, overall survival (OS), progression-free survival 1 (PFS1), and progression-free survival 2 (PFS2) were assessed for both cohorts. Median time to event was tested by Kaplan-Meier method and log-rank test. The Cox-proportional hazards model was used for univariate and multivariate regression analyses.RESULTS: Overall, 196 patients were included. The AA+ADT cohort had a longer PFS1 in the log-rank testing (23 vs. 13 mos., p < 0.001), a longer PFS2 (48 vs. 33 mos., p = 0.006), and longer OS (80 vs. 61 mos., p = 0.040). In the multivariate analyses AA+ADT outperformed D+ADT in terms of PFS1 (HR = 0.34, 95% CI = 0.183-0.623; p = 0.001) and PFS2 (HR = 0.33 95% CI = 0.128-0.827; p = 0.018), respectively, while OS and toxicity rate were similar between both groups.CONCLUSIONS: AA+ADT is mainly associated with a similar efficacy and overall toxicity rate as D+ADT. Further prospective research is required for validation of the clinical value of the observed benefit of AA+ADT for progression-free end-points.

U2 - 10.1002/cam4.4184

DO - 10.1002/cam4.4184

M3 - SCORING: Journal article

C2 - 34374489

VL - 10

SP - 6354

EP - 6364

JO - CANCER MED-US

JF - CANCER MED-US

SN - 2045-7634

IS - 18

ER -